Interim Report for the 9 months ended September 30, 2008

October 29, 2008 12:46 ET | Source: Genmab A/S Genmab A/S

In order to read Genmab's Interim Report for the 9 months ended September 30,
2008, please see the attached file.

Attachments

50_q3_interimreport2008_291008_uk.pdf

50_q3_interimreport2008_291008_uk.pdf...

Recommended Reading

July 23, 2026 16:00 ET | Source: Genmab A/S

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and...
Read More

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$
July 15, 2026 06:22 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity...
Read More